Table 2.
Sentinel lymph node identification—per patient.
| n = 534 | Nordic Trial (2 mL) n = 206 | Sentidose Trial (1.5 mL) n = 163 | Sentidose Trial (1.0 mL) n = 165 | p-Value |
|---|---|---|---|---|
| SPIO SLN detection rate (%) | ||||
| If magnetic signal > 0 | 97.6 | 97.5 | 100 | 0.110 * |
| If magnetic signal > 20 | 97.1 | 95.7 | 100 | 0.016 * |
| SPIO SLN detection rate, malignancy (%) | ||||
| If magnetic signal > 0 | 96.3 | 97.0 | 100 | 0.796 # |
| If magnetic signal > 20 | 94.4 | 97.0 | 100 | 0.693 # |
| SPIO-RI SLN concordance (%) | ||||
| If magnetic signal > 0 | 98.0 | 97.8 | 100 | 0.115 # |
| If magnetic signal > 20 | 97.5 | 93.8 | 100 | 0.265 # |
| SPIO-RI SLN concordance, malignancy (%) | ||||
| If magnetic signal > 0 | 98.1 | 97 | 100 | 1.000 # |
| If magnetic signal > 20 | 96.2 | 100 | 100 | 1.000 # |
#: Pearson’s χ2 test. * Detection rates compared with Fisher’s exact test. Concordance calculated on cross-tabulations with use of the McNemar’s test. SPIO: superparamagnetic iron oxide nanoparticles, SLN: sentinel lymph node, RI: radioisotope.